NUWIQ® – Proven Efficacy
POWERFUL BLEEDING CONTROL
Prophylaxis With NUWIQ Markedly Reduced Bleeding Frequency1
In Clinical Trials of Standard Prophylaxis With NUWIQ in Adult (N=32) and Pediatric (N=59) Patients Treated for ≥6 Months1,*
ZERO
Median ABR
Spontaneous Bleeds
Adults and Children
In Adults
Median ABR for All Bleeds is 0.9
In Children
Median ABR for All Bleeds is 1.9
All Patients Experienced Fewer Bleeds with NUWIQ Prophylaxis vs On-Demand Treatment With Another FVIII Product1,2,†
Patients were switched from on-demand therapy (pre-study) with another FVIII product
to prophylaxis with NUWIQ
Prophylaxis Treatment with NUWIQ in Adults
in a study with 32 adults treated with prophylaxis for 6 months or more (median Annualized Bleed Rate (ABR) was 0.9)
Prophylaxis treatment with NUWIQ in Children
in a study with 59 children treated with prophylaxis for 6 months or more (median Annualized Bleed Rate (ABR) was 1.9)
EFFECTIVE BLEEDING RESOLUTION
On-Demand Treatment Readily Controlled Bleeding3,4
In Adults Patients Receiving On-Demand Treatment with NUWIQ
N=986 bleeds evaluated
Bleeds Resolved With 1 Infusion
Bleeds Resolved
With 1 or 2 Infusions
Control and Prevention of Bleeding During and After Surgery1
Thirty three surgical procedures (N=19)
In 100% of minor surgeries hemostasis rated as "excellent"
In 92% of major surgeries hemostasis rated as "excellent" or "good"
References
- NUWIQ full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.
- Data on file. Paramus, NJ: Octapharma USA, Inc; 2015.
- Valentino LA, et al. Haemophilia.2014;20 (Suppl. 1), 1–9.
- Kessler C, et al. Haemophilia. 2015;21(Suppl. 1): 1–12.